Shanghai Hengrui Pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical subsidiary of Hengrui, developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail aims to shrink Hard-to-Treat lung tumors Results expected Oct 2026 (estimated)
- New drug combo aims to wipe out lung cancer before surgery Results expected Oct 2026 (estimated)
- Experimental injection SHR-7787 put to the test against advanced solid tumors Results expected Dec 2026 (estimated)
- New asthma drug shows promise in reducing severe attacks Results expected Dec 2026 (estimated)
- New drug combo HRS8807 and SHR6390 targets tough breast cancer Results expected Dec 2026 (estimated)
-
Alzheimer's drug trial halted early – no breakthrough yet
Disease control Stopped earlyThis study tested an experimental drug called SHR-1707 in people with mild memory problems or mild Alzheimer's disease. The goal was to see if it could safely reduce harmful protein clumps in the brain. The trial was stopped early, and it is not expected to cure the disease.
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill aims to stop blood clots after knee surgery – but trial halted early
Prevention Stopped earlyThis study tested a new oral blood thinner called SHR2285 in people having knee replacement surgery. The goal was to see if it could prevent dangerous blood clots as well as the standard injection enoxaparin. The trial was planned for 64 participants but was terminated early, so …
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC